Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioPlus Acquisition Corp.BIOS · Entity 112459 | Director | December 02, 2021 | December 02, 2021 |
| Epiphany Technology Acquisition Corp.EPHY · Entity 123266 | Director | September 16, 2022 | October 04, 2022 |
| NewAmsterdam Pharma Co N.V.NAMS · Entity 1826 | Director | March 11, 2026 | March 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioPlus Acquisition Corp.
Report date December 02, 2021 · Filed December 02, 2021
This filing explicitly reported no securities owned.
Epiphany Technology Acquisition Corp.
Report date September 16, 2022 · Filed October 04, 2022
This filing explicitly reported no securities owned.
NewAmsterdam Pharma Co N.V.
Report date March 11, 2026 · Filed March 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 10,360 |
Ending reported balance
After 2026-03-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-11 · Sale · Disposed 44,173 · Balance 10,806 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.11 per share to $31.08 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Row 2 · 2026-03-11 · Sale · Disposed 446 · Balance 10,360 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.13 per share to $31.31 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.11 per share to $31.08 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.13 per share to $31.31 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Audentes Therapeutics, Inc.
Report date January 15, 2020 · Filed January 15, 2020
Section 16 reporting ended · disclosed 2020-01-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 1
1 source rowRow 1 · 2020-01-15 · Other · Disposed 265,799 · Balance 0 F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. |
| Common StockSEC Table I · non-derivative | IndirectBy Amygdala Lange Trust | 0 |
Reported balance
After 2020-01-15 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2020-01-15 · Other · Disposed 13,678 · Balance 0 F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2: The reporting person's spouse is the trustee of the Amygdala Lange Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. |
| Common StockSEC Table I · non-derivative | IndirectBy Asset Management Ventures Fund, L.P. | 0 |
Reported balance
After 2020-01-15 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2020-01-15 · Other · Disposed 32,343 · Balance 0 F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F3: The reporting person is a general partner of Asset Management Ventures Fund, L.P. ("AMVF L.L.P."), and has shared voting and dispositive power over the shares held by AMVF L.L.P. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. |
| Common StockSEC Table I · non-derivative | IndirectBy Adrienne M. MacMillan Revocable Trust( | 0 |
Reported balance
After 2020-01-15 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2020-01-15 · Other · Disposed 3,555 · Balance 0 F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F4: The reporting person's spouse is the trustee of the Adrienne M. MacMillan Revocable Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.03 · Expires 2026-08-24 | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-01-15 · Disposition to issuer · Disposed 18,000 · Balance 0 F5: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.15 · Expires 2027-10-08 | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-01-15 · Disposition to issuer · Disposed 9,000 · Balance 0 F6: Reflects the correct exercise price of this option. The exercise price of this option was previously reported as $26.01. F5: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.65 · Expires 2028-06-08 | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-01-15 · Disposition to issuer · Disposed 10,000 · Balance 0 F5: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.74 · Expires 2029-02-06 | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-01-15 · Disposition to issuer · Disposed 16,200 · Balance 0 F5: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price.
F2: The reporting person's spouse is the trustee of the Amygdala Lange Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
F3: The reporting person is a general partner of Asset Management Ventures Fund, L.P. ("AMVF L.L.P."), and has shared voting and dispositive power over the shares held by AMVF L.L.P. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
F4: The reporting person's spouse is the trustee of the Adrienne M. MacMillan Revocable Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
F5: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
F6: Reflects the correct exercise price of this option. The exercise price of this option was previously reported as $26.01.
GILEAD SCIENCES, INC.
Report date June 01, 2009 · Filed June 05, 2009
Section 16 reporting ended · disclosed 2009-06-05. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 06, 2009 Filed May 8, 2009 21:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 100,000 | $0.00 Strike: $44.03 | $0.00 |
DisclosureSEC source: 0001179110-09-007476 · edgar.xml · derivative · entry 1 LANGE LOUIS G · CIK 0001238401 · EVP Cardiovascular Therapeutic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2019-05-06 F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options will vest on May 6, 2010, the first anniversary date of the grant. The balance will vest 5% every three months thereafter until fully vested on May 6, 2014. Read SEC document |
| April 17, 2009 Filed Apr 27, 2009 21:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon Qualified Stock Option (right to buy) · Derivative | 324 | Not disclosed Strike: $30.83 | Not disclosed |
DisclosureSEC source: 0001179110-09-006796 · edgar.xml · derivative · entry 5 LANGE LOUIS G · CIK 0001238401 · EVP Cardiovascular Therapeutic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324 Underlying: Common Stock · 324 shares Expires 2016-12-11 F6 · price: Received in the Acquisition in exchange for an employee stock option to acquire 36,000 shares of CVT common stock at an exercise price of $13.33 per share. F1 · derivative.exercise_date: Options are fully vested. Read SEC document |
| April 17, 2009 Filed Apr 27, 2009 21:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon Qualified Stock Option (right to buy) · Derivative | 15,570 | Not disclosed Strike: $57.67 | Not disclosed |
DisclosureSEC source: 0001179110-09-006796 · edgar.xml · derivative · entry 4 LANGE LOUIS G · CIK 0001238401 · EVP Cardiovascular Therapeutic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,570 Underlying: Common Stock · 15,570 shares Expires 2015-12-05 F5 · price: Received in the Acquisition in exchange for an employee stock option to acquire 36,000 shares of CVT common stock at an exercise price of $24.94 per share. F1 · derivative.exercise_date: Options are fully vested. Read SEC document |
| April 17, 2009 Filed Apr 27, 2009 21:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon Qualified Stock Option (right to buy) · Derivative | 54,062 | Not disclosed Strike: $53.67 | Not disclosed |
DisclosureSEC source: 0001179110-09-006796 · edgar.xml · derivative · entry 3 LANGE LOUIS G · CIK 0001238401 · EVP Cardiovascular Therapeutic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,062 Underlying: Common Stock · 54,062 shares Expires 2012-12-02 F4 · price: Received in the Acquisition in exchange for an employee stock option to acquire 125,000 shares of CVT common stock at an exercise price of $23.21 per share. F1 · derivative.exercise_date: Options are fully vested. Read SEC document |
| April 17, 2009 Filed Apr 27, 2009 21:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon Qualified Stock Option (right to buy) · Derivative | 21,625 | Not disclosed Strike: $93.90 | Not disclosed |
DisclosureSEC source: 0001179110-09-006796 · edgar.xml · derivative · entry 2 LANGE LOUIS G · CIK 0001238401 · EVP Cardiovascular Therapeutic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,625 Underlying: Common Stock · 21,625 shares Expires 2011-10-31 F3 · price: Received in the Acquisition in exchange for an employee stock option to acquire 50,000 shares of CVT common stock at an exercise price of $40.61 per share. F1 · derivative.exercise_date: Options are fully vested. Read SEC document |
| April 17, 2009 Filed Apr 27, 2009 21:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon Qualified Stock Option (right to buy) · Derivative | 43,250 | Not disclosed Strike: $85.84 | Not disclosed |
DisclosureSEC source: 0001179110-09-006796 · edgar.xml · derivative · entry 1 LANGE LOUIS G · CIK 0001238401 · EVP Cardiovascular Therapeutic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,250 Underlying: Common Stock · 43,250 shares Expires 2010-05-16 F2 · price: Received in the acquisition of CV Therapeutics, Inc. ("CVT") by Gilead Sciences, Inc. (the "Acquisition") in exchange for an employee stock option to acquire 100,000 shares of CVT common stock at an exercise price of $37.125 per share. F1 · derivative.exercise_date: Options are fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.